![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CNTRL |
Gene summary for CNTRL |
![]() |
Gene information | Species | Human | Gene symbol | CNTRL | Gene ID | 11064 |
Gene name | centriolin | |
Gene Alias | CEP1 | |
Cytomap | 9q33.2 | |
Gene Type | protein-coding | GO ID | GO:0001568 | UniProtAcc | B2RP65 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11064 | CNTRL | C21 | Human | Oral cavity | OSCC | 8.28e-06 | 2.07e-01 | 0.2678 |
11064 | CNTRL | C30 | Human | Oral cavity | OSCC | 9.16e-13 | 5.45e-01 | 0.3055 |
11064 | CNTRL | C38 | Human | Oral cavity | OSCC | 3.56e-06 | 5.67e-01 | 0.172 |
11064 | CNTRL | C43 | Human | Oral cavity | OSCC | 2.36e-07 | 4.91e-02 | 0.1704 |
11064 | CNTRL | C46 | Human | Oral cavity | OSCC | 3.05e-12 | 1.70e-01 | 0.1673 |
11064 | CNTRL | C08 | Human | Oral cavity | OSCC | 1.16e-06 | 1.01e-01 | 0.1919 |
11064 | CNTRL | EOLP-1 | Human | Oral cavity | EOLP | 4.35e-15 | 3.02e-01 | -0.0202 |
11064 | CNTRL | NEOLP-2 | Human | Oral cavity | NEOLP | 2.50e-04 | 1.47e-01 | -0.0196 |
11064 | CNTRL | NEOLP-3 | Human | Oral cavity | NEOLP | 3.87e-03 | 1.50e-01 | -0.0191 |
11064 | CNTRL | SYSMH1 | Human | Oral cavity | OSCC | 2.53e-07 | 1.07e-01 | 0.1127 |
11064 | CNTRL | SYSMH2 | Human | Oral cavity | OSCC | 1.45e-08 | 2.13e-01 | 0.2326 |
11064 | CNTRL | SYSMH3 | Human | Oral cavity | OSCC | 3.86e-09 | 1.82e-01 | 0.2442 |
11064 | CNTRL | HTA12-23-1 | Human | Pancreas | PDAC | 4.22e-05 | 6.43e-01 | 0.3405 |
11064 | CNTRL | HTA12-26-1 | Human | Pancreas | PDAC | 2.53e-09 | 5.90e-01 | 0.3728 |
11064 | CNTRL | HTA12-29-1 | Human | Pancreas | PDAC | 4.91e-14 | 4.19e-01 | 0.3722 |
11064 | CNTRL | GSM5252126_BPH283PrGF_Via | Human | Prostate | BPH | 1.42e-07 | 5.46e-02 | -0.1771 |
11064 | CNTRL | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 1.70e-02 | 2.03e-02 | -0.2126 |
11064 | CNTRL | 048752_1579-all-cells | Human | Prostate | BPH | 7.72e-04 | 1.79e-01 | 0.1008 |
11064 | CNTRL | 052095_1628-all-cells | Human | Prostate | BPH | 7.08e-04 | 1.84e-01 | 0.1032 |
11064 | CNTRL | Dong_P1 | Human | Prostate | Tumor | 1.00e-10 | 4.13e-02 | 0.035 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00016558 | Oral cavity | OSCC | urogenital system development | 160/7305 | 338/18723 | 1.03e-03 | 5.31e-03 | 160 |
GO:000165514 | Oral cavity | NEOLP | urogenital system development | 58/2005 | 338/18723 | 1.97e-04 | 2.13e-03 | 58 |
GO:00032312 | Oral cavity | NEOLP | cardiac ventricle development | 27/2005 | 123/18723 | 2.14e-04 | 2.27e-03 | 27 |
GO:0060840 | Oral cavity | NEOLP | artery development | 23/2005 | 100/18723 | 3.00e-04 | 2.97e-03 | 23 |
GO:00032814 | Oral cavity | NEOLP | ventricular septum development | 17/2005 | 71/18723 | 1.10e-03 | 8.28e-03 | 17 |
GO:00032053 | Oral cavity | NEOLP | cardiac chamber development | 30/2005 | 161/18723 | 1.78e-03 | 1.22e-02 | 30 |
GO:00720017 | Oral cavity | NEOLP | renal system development | 47/2005 | 302/18723 | 5.60e-03 | 2.97e-02 | 47 |
GO:00032793 | Oral cavity | NEOLP | cardiac septum development | 20/2005 | 103/18723 | 6.01e-03 | 3.13e-02 | 20 |
GO:00018226 | Oral cavity | NEOLP | kidney development | 45/2005 | 293/18723 | 8.36e-03 | 4.08e-02 | 45 |
GO:00016557 | Prostate | BPH | urogenital system development | 88/3107 | 338/18723 | 6.05e-06 | 8.83e-05 | 88 |
GO:00720016 | Prostate | BPH | renal system development | 76/3107 | 302/18723 | 8.55e-05 | 8.09e-04 | 76 |
GO:00018225 | Prostate | BPH | kidney development | 74/3107 | 293/18723 | 9.31e-05 | 8.76e-04 | 74 |
GO:00032813 | Prostate | BPH | ventricular septum development | 23/3107 | 71/18723 | 7.95e-04 | 5.21e-03 | 23 |
GO:0003231 | Prostate | BPH | cardiac ventricle development | 34/3107 | 123/18723 | 1.37e-03 | 8.20e-03 | 34 |
GO:00032792 | Prostate | BPH | cardiac septum development | 29/3107 | 103/18723 | 2.20e-03 | 1.22e-02 | 29 |
GO:00032052 | Prostate | BPH | cardiac chamber development | 41/3107 | 161/18723 | 2.63e-03 | 1.41e-02 | 41 |
GO:000165513 | Prostate | Tumor | urogenital system development | 90/3246 | 338/18723 | 1.08e-05 | 1.56e-04 | 90 |
GO:000182213 | Prostate | Tumor | kidney development | 74/3246 | 293/18723 | 3.68e-04 | 2.87e-03 | 74 |
GO:007200113 | Prostate | Tumor | renal system development | 75/3246 | 302/18723 | 5.74e-04 | 4.13e-03 | 75 |
GO:00032311 | Prostate | Tumor | cardiac ventricle development | 36/3246 | 123/18723 | 7.31e-04 | 5.08e-03 | 36 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CNTRL | deletion | Frame_Shift_Del | c.5399delN | p.Lys1802SerfsTer9 | p.K1802Sfs*9 | Q7Z7A1 | protein_coding | TCGA-BR-A4QL-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | CR | |||
CNTRL | deletion | Frame_Shift_Del | rs747099268 | c.1328delN | p.Ile446Ter | p.I446* | Q7Z7A1 | protein_coding | TCGA-HF-7132-01 | Stomach | stomach adenocarcinoma | Male | Unknown | I/II | Chemotherapy | fluorouracil | SD | ||
CNTRL | deletion | Frame_Shift_Del | c.5399delN | p.Lys1802SerfsTer9 | p.K1802Sfs*9 | Q7Z7A1 | protein_coding | TCGA-HU-A4H8-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | didox | PD | |||
CNTRL | deletion | Frame_Shift_Del | c.5399delN | p.Lys1802SerfsTer9 | p.K1802Sfs*9 | Q7Z7A1 | protein_coding | TCGA-VQ-A8PB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR | |||
CNTRL | SNV | Missense_Mutation | rs764334541 | c.6740N>A | p.Arg2247Gln | p.R2247Q | Q7Z7A1 | protein_coding | tolerated(0.09) | benign(0.012) | TCGA-BJ-A2NA-01 | Thyroid | thyroid carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
CNTRL | insertion | Frame_Shift_Ins | novel | c.6502_6503insGA | p.Ile2168ArgfsTer6 | p.I2168Rfs*6 | Q7Z7A1 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |